Cargando…

Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients

BACKGROUND: Circulating tumour cells (CTCs) are attractive “liquid biopsy” candidates that could provide insights into the different phenotypes of tumours present within a patient. The epithelial-to-mesenchymal transition (EMT) of CTCs is considered a critical step in tumour metastasis; however, it...

Descripción completa

Detalles Bibliográficos
Autores principales: Acheampong, Emmanuel, Morici, Michael, Abed, Afaf, Bowyer, Samantha, Asante, Du-Bois, Lin, Weitao, Millward, Michael, Gray, Elin S., Beasley, Aaron B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097753/
https://www.ncbi.nlm.nih.gov/pubmed/35896898
http://dx.doi.org/10.1007/s00432-022-04202-y
_version_ 1785024639896911872
author Acheampong, Emmanuel
Morici, Michael
Abed, Afaf
Bowyer, Samantha
Asante, Du-Bois
Lin, Weitao
Millward, Michael
Gray, Elin S.
Beasley, Aaron B.
author_facet Acheampong, Emmanuel
Morici, Michael
Abed, Afaf
Bowyer, Samantha
Asante, Du-Bois
Lin, Weitao
Millward, Michael
Gray, Elin S.
Beasley, Aaron B.
author_sort Acheampong, Emmanuel
collection PubMed
description BACKGROUND: Circulating tumour cells (CTCs) are attractive “liquid biopsy” candidates that could provide insights into the different phenotypes of tumours present within a patient. The epithelial-to-mesenchymal transition (EMT) of CTCs is considered a critical step in tumour metastasis; however, it may confound traditional epithelial feature-based CTC isolation and detection. We applied single-cell copy number alteration (CNA) analysis for the identification of genomic alterations to confirm the neoplastic nature of circulating cells with only mesenchymal phenotypes. METHODS: We isolated CTCs from blood samples collected from 46 NSCLC patients using the Parsortix system. Enriched cells were subjected to immunofluorescent staining for CTC identification using a multi-marker panel comprising both epithelial and mesenchymal markers. A subset of isolated CTCs was subjected to whole genome amplification (WGA) and low-pass whole-genome sequencing (LP-WGS) for the analysis of copy number alterations (CNAs). RESULTS: CTCs were detected in 16/46 (34.8%) patients, inclusive of CK(+)/EpCAM(+) CTCs (3/46, 6.5%) and Vim(+) CTCs (13/46, 28.3%). Clusters of Vim(+) cells were detected in 8 samples, which constitutes 50% of the total number of NSCLC patients with CTCs. No patients had detectable hybrid CK(+)/EpCAM(+)/Vim(+) cells. All of the tested CK(+)/EpCAM(+) CTCs and 7/8 Vim(+) CTCs or CTC clusters carried CNAs confirming their neoplastic nature. Notably, the Vim(+) cluster with no CNAs was characterised by spindle morphology and, therefore, defined as normal mesenchymal circulating cells. CONCLUSION: Our results revealed that CK-negative, vimentin-expressing cells represent a large proportion of CTCs detected in NSCLC patients, which are likely missed by standard epithelial-marker-dependent CTC categorisation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-022-04202-y.
format Online
Article
Text
id pubmed-10097753
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-100977532023-04-14 Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients Acheampong, Emmanuel Morici, Michael Abed, Afaf Bowyer, Samantha Asante, Du-Bois Lin, Weitao Millward, Michael Gray, Elin S. Beasley, Aaron B. J Cancer Res Clin Oncol Original Article – Clinical Oncology BACKGROUND: Circulating tumour cells (CTCs) are attractive “liquid biopsy” candidates that could provide insights into the different phenotypes of tumours present within a patient. The epithelial-to-mesenchymal transition (EMT) of CTCs is considered a critical step in tumour metastasis; however, it may confound traditional epithelial feature-based CTC isolation and detection. We applied single-cell copy number alteration (CNA) analysis for the identification of genomic alterations to confirm the neoplastic nature of circulating cells with only mesenchymal phenotypes. METHODS: We isolated CTCs from blood samples collected from 46 NSCLC patients using the Parsortix system. Enriched cells were subjected to immunofluorescent staining for CTC identification using a multi-marker panel comprising both epithelial and mesenchymal markers. A subset of isolated CTCs was subjected to whole genome amplification (WGA) and low-pass whole-genome sequencing (LP-WGS) for the analysis of copy number alterations (CNAs). RESULTS: CTCs were detected in 16/46 (34.8%) patients, inclusive of CK(+)/EpCAM(+) CTCs (3/46, 6.5%) and Vim(+) CTCs (13/46, 28.3%). Clusters of Vim(+) cells were detected in 8 samples, which constitutes 50% of the total number of NSCLC patients with CTCs. No patients had detectable hybrid CK(+)/EpCAM(+)/Vim(+) cells. All of the tested CK(+)/EpCAM(+) CTCs and 7/8 Vim(+) CTCs or CTC clusters carried CNAs confirming their neoplastic nature. Notably, the Vim(+) cluster with no CNAs was characterised by spindle morphology and, therefore, defined as normal mesenchymal circulating cells. CONCLUSION: Our results revealed that CK-negative, vimentin-expressing cells represent a large proportion of CTCs detected in NSCLC patients, which are likely missed by standard epithelial-marker-dependent CTC categorisation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-022-04202-y. Springer Berlin Heidelberg 2022-07-28 2023 /pmc/articles/PMC10097753/ /pubmed/35896898 http://dx.doi.org/10.1007/s00432-022-04202-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article – Clinical Oncology
Acheampong, Emmanuel
Morici, Michael
Abed, Afaf
Bowyer, Samantha
Asante, Du-Bois
Lin, Weitao
Millward, Michael
Gray, Elin S.
Beasley, Aaron B.
Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients
title Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients
title_full Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients
title_fullStr Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients
title_full_unstemmed Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients
title_short Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients
title_sort powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients
topic Original Article – Clinical Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097753/
https://www.ncbi.nlm.nih.gov/pubmed/35896898
http://dx.doi.org/10.1007/s00432-022-04202-y
work_keys_str_mv AT acheampongemmanuel poweringsinglecellgenomicstounravelcirculatingtumourcellsubpopulationsinnonsmallcelllungcancerpatients
AT moricimichael poweringsinglecellgenomicstounravelcirculatingtumourcellsubpopulationsinnonsmallcelllungcancerpatients
AT abedafaf poweringsinglecellgenomicstounravelcirculatingtumourcellsubpopulationsinnonsmallcelllungcancerpatients
AT bowyersamantha poweringsinglecellgenomicstounravelcirculatingtumourcellsubpopulationsinnonsmallcelllungcancerpatients
AT asantedubois poweringsinglecellgenomicstounravelcirculatingtumourcellsubpopulationsinnonsmallcelllungcancerpatients
AT linweitao poweringsinglecellgenomicstounravelcirculatingtumourcellsubpopulationsinnonsmallcelllungcancerpatients
AT millwardmichael poweringsinglecellgenomicstounravelcirculatingtumourcellsubpopulationsinnonsmallcelllungcancerpatients
AT grayelins poweringsinglecellgenomicstounravelcirculatingtumourcellsubpopulationsinnonsmallcelllungcancerpatients
AT beasleyaaronb poweringsinglecellgenomicstounravelcirculatingtumourcellsubpopulationsinnonsmallcelllungcancerpatients